Chronic idiopathic neutropenia: Find the most comprehensive real-world symptom and treatment data on chronic idiopathic neutropenia at PatientsLikeMe. 10 patients with chronic idiopathic neutropenia experience fatigue, depressed mood, pain, anxious mood, and insomnia.
Severe chronic neutropenia (SCN) is defined as an absolute neutrophil (ANC) of less than 0.5 x 10(9)/L, lasting for months or years. Congenital, cyclic, and idiopathic neutropenia are principal categories of SCN. Since 1994, the Severe Chronic Neutropenia International Registry (SCNIR) has collected data to monitor the clinical course, treatments, and disease outcomes for SCN patients. This report summarizes data for 853 patients, almost all treated with daily or alternate-day recombinant human granulocyte colony-stimulating factor (G-CSF or Filgrastim). G-CSF treatment increased the ANC overall from 0.34 x 10(9)/L +/- 0.018 pre-treatment to 3.70 x 10(9)/L +/- 0.18 during the first year of treatment. For most patients, the responses were durable with patients remaining on the same dose of G-CSF for many years. Long-term hematological observations showed stable mean leukocyte and neutrophil counts and gradually increasing hemoglobin levels. Thrombocytopenia developed in 4% of patients. As of ...
Severe chronic neutropenia may be present at birth (congenital neutropenia) or may occur at any stage in life (acquired neutropenia). There are four main types of severe chronic neutropenia:. Congenital Neutropenia - a rare inherited form of the disease usually detected soon after birth. It affects children mainly and may result in premature loss of teeth and peremptory gum infections. The most severe form of chronic congenital neutropenia is known as Kostmanns Syndrome.. Cyclic Neutropenia - tends to occur every three weeks and lasting three to six days at a time due to changing rates of cell production by the bone marrow. It is often present among several members of the same family although improves after puberty in most cases. This is the rarest form of severe chronic neutropenia.. Idiopathic Neutropenia - a rare form of neutropenia which develops in children and adults usually in response to an illness. It is diagnosed when the disorder cannot be attributed to any other diseases and often ...
The European branch of the SCNIR is actively cooperating with pediatricians and hematologists all over Europe. Since December 2001 the activities of the European neutropenia network are being supported by a grant of the European Commission in the program Rare Diseases. Thanks to the funding of the EU Commission, an Internet-accessible database system was acquired that enables all centers participating in the SCNIR to get the most pertinent information on severe chronic neutropenia directly via the Internet.. The SCNIR collects both, general and specific clinical information, e.g. on malignant transformation, bone marrow transplantation and outcome etc., on patients with severe chronic neutropenia. All information arising from the database of the European Branch of the Severe Chronic Neutropenia International Registry is disseminated among the members of this network in order to provide an update of the professional skills of the European network partners, which in turn is passed on to other ...
Kostmann, R. "Infantile genetic agranulocytosis. A new recessive lethal disease in man". Acta Paediatr. vol. 105. 1956. pp. 1-78. [Severe congenital neutropenia was first described as an autosomal recessive disorder associated with severe neutropenia that was identified in a population of an isolated northern parish in Sweden. It was characterized by a deficiency of a mature neutrophil in the bone marrow and peripheral blood.] Klein, C, Grudzien, M, Appaswamy, G. "HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease)". Nat Genetics. vol. 30. 2007. pp. 86-92. [Using a genome linkage study in candidate gene sequencing in consanguineous pedigrees with severe congenital neutropenia, mutations in HAX1 were identified.] Dale, DC, Person, RE, Bolyard, AA. "Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia". Blood. vol. 96. 2000. pp. 2317-2322. [This study documented that constitutive mutations in the ELANE gene (encoding ...
Autoimmune neutropenia is a form of neutropenia which is most common in infants and young children where the body identifies the neutrophils as enemies and makes antibody to destroy them. Primary autoimmune neutropenia (AIN) is an autoimmune disease first reported in 1975 that primarily occurs in infancy. In autoimmune neutropenia, the immune system produces autoantibodies directed against the neutrophilic protein antigens in white blood cells known as granulocytic neutrophils (granulocytes, segmented neutrophils, segs, polysegmented neutrophils, polys). These antibodies destroy granulocytic neutrophils. Consequently, patients with autoimmune neutropenia have low levels of granulocytic neutrophilic white blood cells causing a condition of neutropenia. Neutropenia causes an increased risk of infection from organisms that the body could normally fight easily. Who is Affected? Primary autoimmune neutropenia has been reported as early as the second month of life although most cases are diagnosed in ...
Severe Chronic Neutropenia International Registry, info about Conditions and Diseases: Blood Disorders: Neutropenia: Severe Chronic Neutropenia International Registry
We describe the first case of chronic neutropenia of 17 years duration following gold therapy in a 53-year-old woman given a 1-g course of gold therapy in 1965 for treatment of seropositive rheumatoid arthritis. Although she had a good response to the gold therapy, her originally normal leukocyte count fell to 1.2 x 10(9)/L. Over the subsequent 17 years, she required multiple hospitalizations for recurrent skin, mouth, and respiratory tract infections. Serial leukocyte counts failed to show a cyclical nature to the chronic neutropenia. Normal results of a technetium Tc 99m spleen scan and lack of increased bone marrow leukocyte precursors rendered a diagnosis of Feltys syndrome unlikely. A bone marrow biopsy specimen revealed an isolated reduction in the number of myeloid precursors, which is consistent with gold-induced bone marrow toxicity. This patients relative freedom from serious life-threatening infections remains enigmatic, but is undoubtedly related to her ability to augment another ...
Visit For Sample Pages:. https://www.delveinsight.com/sample-request/chemotherapy-induced-febrile-neutropenia-market. Key Benefits of Chemotherapy Induced Febrile Neutropenia Market Report. Chemotherapy Induced Febrile Neutropenia market report provides an in-depth analysis of Chemotherapy Induced Febrile Neutropenia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.. The Chemotherapy Induced Febrile Neutropenia market report will help in developing business strategies by understanding the Chemotherapy Induced Febrile Neutropenia Market trends & developments, key players and future market competition that will shape and drive the Chemotherapy Induced Febrile Neutropenia market in the upcoming years.. The Chemotherapy Induced Febrile Neutropenia market report covers Chemotherapy Induced Febrile Neutropenia current treatment practices, emerging drugs, market share of the ...
Genetic Heterogeneity of Severe Congenital Neutropenia Severe congenital neutropenia is a genetically heterogeneous disorder showing autosomal dominant, autosomal recessive, and X-linked inheritance. Autosomal dominant SCN2 ({613107}) is caused by mutation in the protooncogene GFI1 ({600871}) on chromosome 1p22. Autosomal recessive SCN3 ({610738}) is caused by mutation in the HAX1 gene ({605998}) on 1q21.3; autosomal recessive SCN4 ({612541}) is caused by mutation in the G6PC3 gene ({611045}) on 17q21; autosomal recessive SCN5 ({615285}) is caused by mutation in the VPS45 gene ({610035}) on 1q; autosomal recessive SCN6 ({616022}) is caused by mutation in the JAGN1 gene ({616012}) on 3p25; and autosomal recessive SCN7 ({617014}) is caused by mutation in the CSF3R gene ({138971}) on 1p34. X-linked SCN (SCNX; {300299}) is caused by mutation in the WAS gene ({300392}) on Xp11. For associations pending confirmation, see MOLECULAR GENETICS. See also adult chronic idiopathic nonimmune neutropenia ...
The maximum value in this system is 26, and a score of ,21 predicts a ,5% risk for severe complications and a very low mortality (,1%) in febrile neutropenic patients.. References: ...
Early misdiagnosis is a common issue for patients and families with Neutropenia. In order to officially determine Neutropenia a physician will need to run a Complete Blood Count (CBC), which is also known as a Full Blood Count (FBC). These procedures directly measure the neutrophil count.. Patients with Severe Chronic Neutropenia (SCN) may have a neutrophil count which varies slightly.. Though, in contrast to Cyclic Neutropenia it always remains at a very low level. With Cyclic Neutropenia counts can test normal due to a cyclical change, but may test very low at other times. Testing for Cyclic usually involves CBCs taken three times per week for at least six weeks to see if a regular cyclical pattern of neutrophil counts.. Physicians should also do a blood test to exclude autoimmune Neutropenia by testing for neutrophil antibodies.. ...
as cyclical neutropenia and Grey Collie Syndrome, is an inherited blood disorder that results due to an autosomal dominant cell mutating. This disorder causes extremely low neutrophil blood levels in the body. Neutrophils are better known as white blood cells and they aid the body in fighting off infections. With this recurring condition, it approximately occurs every three weeks, while lasting anywhere from three to six days. When neutrophil level are low, the pet may be prone to more frequent infections. Symptoms of cyclic neutropenia are joint pain, diarrhea, skin infections, mouth ulcers, fevers, and frequent infections. Collie dog breeds tend to be the most common breed that suffers from this condition. Unfortunately there is no current cure available for pets who suffer from cyclic neutropenia, however, there are some medications your veterinarian can prescribe that may prolong your cat or dogs life by several years.. To learn more about Cyclic Neutropenia in pets, check out our Pet Health ...
Find the best chronic autoimmune neutropenia doctors in Gurgaon. Get guidance from medical experts to select chronic autoimmune neutropenia specialist in Gurgaon from trusted hospitals - credihealth.com
Bolyard, Audrey, Pracht, G., Schwinzer, Beate, Zeidler, Cornelia, Bonilla, Mary Ann, Boxer, Laurence, Cham, Bonnie, Donadieu, J., Fier, Carol, Freedman, Melvin, Kannourakis, George, Kinsey, Sally, Winkelstein, J., Alter, Blanche, Reeves, L., Welte, Karl, Dale, David ...
A recent abstract presented at the American Society of Clinical Oncology (ASCO) annual meeting compared 2 risk models for patients with intermediate chemotherapy-induced neutropenia (CIN) risk and compared them to guidelines from ASCO and the National Comprehensive Cancer Network to determine when colony-stimulating factor should be ideally used to prevent CIN.|br /| ​​​​​​
Looking for information on Chronic Neutropenia? Medigest has all you need to know about Chronic Neutropenia - Symptoms and Signs, Causes, Treatments and definition
Neutropenia is the decrease to the normal Neutrophil count. Neutropenia is defined as the Neutrophil count that less than 2,500 cells/µL.. The normal white blood cell count for the Neutrophil is 8870 segmental (mature) cells/µL in newborns which drops down dramatically within 2 weeks to lower than 2600 cells/µL, then the normal Neutrophil count starts to increase again to reach 3800 cells/µL in adults.. Since the Neutrophil makes up the majority of white blood cells, except at early childhood, a massive decrease in the Neutrophils count (severe Neutropenia) would cause a noticeable decrease in the total blood cells count (Leukopenia) and sometimes the terms Neutropenia and Leukopenia may be used to refer to each other. But Neutropenia is just a subtype of Leukopenia.. Neutrophils are decreased in the circulating blood by exposure to radiation and Neutropenia is considered as a side effect to Radiation Therapy.. Anaphylactic reaction (Anaphylaxis) is another cause of Neutropenia. Anaphylaxis ...
... Jackie Thomson + OBJECTIVE AND OUTCOME  Apporoach to a patient with neutropenic fever  DEFINITION/ABBREVIATION  NF = neutropenic fever  Fever = Fever is defined as a single oral temperature measurement of ,38.0C 30 minutes apart.  Neutropenia = Neutropenia is defined as an ANC of ,500 cells/mm3 or an ANC that is expected to decrease to ,500 cells/mm3 during the next 3 days + approach  The host  The bugs  The tests  The drugs + Risk assesment  When dealing with a patient with neutropenic sepsis please always consider the host first.  RISK FACTORS FOR COMPLICATION OF SEVERE INFECTION IN NEUTROPENIC FEVER  HIGH RISK  Anticipated brief  or no or few comorbidities  Such patients are candidates for oral empirical therapy (A-II) on an outpatient basis  Anticipated prolonged (,7 days duration)  Profound neutropenia (absolute neutrophil count [ANC] ,100 cells/mm3 following cytotoxic chemotherapy)  (,7 days duration) neutropenic ...
Thousands of people each year are hospitalized for neutropenia, which continues to cause substantial morbidity and mortality for those affected. Neutropenia is primarily caused by chemotherapy and various other cancer treatments, such as radiation therapy, biotherapy, and HSC transplantation. Signs and symptoms of neutropenia may include high fever, chills, sore throat, and diarrhea. In neutropenia, the number of neutrophils, a type of granulocyte, is greatly reduced, weakening the bodys immune system and increasing the risk of infection. Therefore, a method to provide adequate numbers of functional granulocytes to people with neutropenia could be of greatest benefit for recovery. Administration of a combination of two drugs, granulocyte colony-stimulating factor (G-CSF) and dexamethasone, has been show to stimulate the body to produce a large number of granulocytes. Granulocyte transfusions obtained from donors who have received these two drugs may help people with low white blood cell counts ...
Neutropenia or neutropaenia is an abnormally low concentration of neutrophils (a type of white blood cell) in the blood. Neutrophils make up the majority of circulating white blood cells and serve as the primary defense against infections by destroying bacteria, bacterial fragments and immunoglobulin-bound viruses in the blood. Patients with neutropenia are more susceptible to bacterial infections and, without prompt medical attention, the condition may become life-threatening (neutropenic sepsis). Neutropenia can be acute (temporary) or chronic (long lasting). The term is sometimes used interchangeably with "leukopenia" ("deficit in the number of white blood cells"). Signs and symptoms of neutropenia include fever, painful swallowing, gingival pain, skin abscesses, and otitis. These symptoms may exist because individuals with neutropenia often have infection Children may show signs of irritability, and poor feeding. Additionally, hypotension has also been observed in individuals who suffer from ...
Cohen Syndrome Families,. For the past several years the Severe Chronic Neutropenia International Registry has been following several of our Cohen Syndrome families. During the 2014 Cohen Syndrome family gathering more families joined the registry. We cannot express how important it is for all of our families to participate in this study and we urge you to contact Audrey Anna Boy B.S from the Severe Chronic Neutropenia International Registry at the contact information below.. This request is for all Cohen Syndrome cases, even if there are no symptoms of Neutropenia as many of our kids so not exhibit clinical symptoms.. A message from Audrey Anna: ...
High-Risk Fever and Neutropenia: Patients with ANY of the following: hematologic malignancy in induction, consolidation or delayed intensification phase of therapy, hematologic malignancy with relapsed or persistent disease, neutropenia anticipated to last , 7 days, significant mucositis, BMT patients before neutrophil engraftment, focus of serious bacterial infection identified (e.g. pneumonia, abscess).. Low-Risk Fever and Neutropenia: Patients with NO High-Risk criteria AND ALL of the following: neutropenia anticipated to last , 7 days, clinically well-appearing, no focus of serious bacterial infection.. Clinically Unstable: ANY of the following: shaking chills or rigors, hypotension, hypothermia, abnormal pulses or capillary refill, respiratory distress or hypoxia, altered mental status, tachycardia out of proportion to fever. These guidelines are specific to patients whose neutropenia is related to chemotherapy or BMT conditioning and may not be appropriate for patients with neutropenia due ...
Dale, David C.; Cottle, Tammy E.; Fier, Carol J.; Bolyard, Audrey Anna; Bonilla, Mary Ann; Boxer, Laurence A.; Cham, Bonnie; Freedman, Melvin H.; Kannourakis, George; Kinsey, Sally E.; Davis, Robert; Scarlata, Debra; Schwinzer, Beate; Zeidler, Cornelia; Welte, Karl (2003). "Severe chronic neutropenia: Treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry". American Journal of Hematology. 72 (2): 82-93. doi:10.1002/ajh.10255. ISSN 0361-8609 ...
TY - JOUR. T1 - First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer. T2 - A multicenter, double-blind, placebo-controlled phase III study. AU - Vogel, Charles. AU - Wojtukiewicz, Marek Z.. AU - Carroll, Robert R.. AU - Tjulandin, Sergei A.. AU - Barajas-Figueroa, Luis Javier. AU - Wiens, Brian L.. AU - Neumann, Theresa A.. AU - Schwartzberg, Lee S.. PY - 2005/2/20. Y1 - 2005/2/20. N2 - Purpose: We evaluated the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia associated with docetaxel in breast cancer patients. Patients and Methods: Patients were randomly assigned to either placebo or pegfilgrastim 6 mg subcutaneously on day 2 of each 21-day chemotherapy cycle of 100 mg/m2 docetaxel. The primary end point was the percentage of patients developing febrile neutropenia (defined as body temperature ≥ 38.2°C and neutrophil count , 0.5 × 109/L on the same day of the fever or the day after). Secondary end points were ...
The aim of this study was to determine predictive factors for neutropenia after docetaxel-based systemic chemotherapy in patients with castration-resistant prostate cancer (CRPC). The study included 40 Korean CRPC patients who were treated with several cycles of docetaxel plus prednisolone from May 2005 to May 2012. Patients were evaluated for neutropenia risk factors and for the incidence of neutropenia. In this study, nine out of forty patients (22.5%) developed neutropenia during the first cycle of docetaxel-based systemic chemotherapy. Four experienced grade 2, three grade 3, and one grade 4 neutropenia. Multivariate analysis showed that pretreatment white blood cell (WBC) count (p=0.042), pretreatment neutrophil count (p=0.015), pretreatment serum creatinine level (p=0.027), and pretreatment serum albumin level (p=0.017) were significant predictive factors for neutropenia. In conclusion, pretreatment WBC counts, neutrophil counts, serum creatinine levels, and serum albumin levels proved to be
Definition, Etiology, PathogenesisTop. Neutropenia is the most common hematologic complication of cancer treatment. It may result from the myelotoxic effects of chemotherapy or radiation therapy or from bone marrow infiltration by malignant cells. In patients with febrile neutropenia the causative pathogen can be identified only in 20% to 30% of cases. Prior to the introduction of empiric therapy for febrile neutropenia, the most frequently identified etiologic agents were Pseudomonas spp and Enterobacteriaceae (eg, Escherichia coli, Klebsiella spp) followed by gram-positive cocci (most commonly Staphylococcus aureus). In the era of empiric therapy, there has been a shift in the microbiology of pathogens to predominantly gram-positive organisms (coagulase-negative staphylococci being the most common) followed by Enterobacteriaceae and then by nonfermenting gram-negative bacilli, such as Pseudomonas aeruginosa.. Febrile neutropenia is defined as: 1) Oral temperature ≥38.3 degrees Celsius in a ...
Typhlitis describes enterocolitis of the ileocaecal region seen commonly in neutropenic patients. As compared with other malignant conditions, acute myeloid leukaemia (AML) is most often associated with typhlitis.1 The pathogenesis of typhlitis probably involves a combination of factors, including mucosal injury by cytotoxic drugs, profound neutropenia and impaired host defence to invasion by microorganisms.2 The most common chemotherapeutics associated with typhlitis are cytarabine and daunorubicin.1 Peritonitis and perforation are … ...
https://kohlab.org/wp-content/uploads/2017/06/utsw-master-logo-lg-300x92.png 0 0 awp-admin https://kohlab.org/wp-content/uploads/2017/06/utsw-master-logo-lg-300x92.png awp-admin2008-02-08 18:27:132017-07-10 20:32:58Mucosal damage and neutropenia are required for Candida albicans dissemination. ...
Understanding Severe Chronic Neutropenia_SCNIR. Severe Chronic Neutropenia International Registry (SCNIR) Medical School Hannover Carl-Neuberg-Str. 1. 30625 Hannover. Germany. Tel +49/511-557105. Fax +49/511-557106. www.scner.de. ...
This cohort offers new information about the hematological and infectious profiles of WS. Interestingly, besides the constant neutropenia and lymphopenia, all 8 patients present monocytopenia and half of the patients present profound monocytopenia below 0.1 G/L, contrasting with the monocytosis commonly observed in other congenital neutropenias, such as the elastase neutrophil expressed (ELANE) syndrome. Of particular note, susceptibility to mycobacterial infections may be added to the infection spectrum of WS. Considering the monocytopenia and the infectious profile, composed by pyogenic infections, warts and mycobacteria, WS presents certain similarities with the Mono-MAC syndrome, now identified as the consequence of GATA2 mutations[53, 54]. The major phenotypic difference between the two syndromes is the BM myelokathexis feature the WS.. We previously reported, in leukocytes derived from two patients (UPN 5231 and 5446) from pedigree 4 carrying a mutated CXCR4 receptor, that the increased ...
Semantic Scholar extracted view of Lactobacillus bacteremia in febrile neutropenic patients in a cancer hospital. by Chris Cooper et al.
The risk is calculated not only by the neutrophil count but by complicating factors as follows:. - The longer the duration of severe neutropenia, the greater the risk of infection.. - The risk of infection is greater when the count is falling rapidly or when there is associated monocytopenia, lymphocytopenia, or hypogammaglobulinemia.. - Neutropenia caused by disorders of hematopoietic progenitor cells (eg, chemotherapy-induced marrow suppression, severe inherited neutropenia) generally results in a greater susceptibility to infections compared with neutropenia resulting from accelerated turnover (eg, immune neutropenia).. - Integrity of the skin and mucous membranes, blood supply to tissues, presence of an indwelling catheter, and nutritional status are also important in considering infection risk.. ...
... occurs in compromised immune systems due to a low number of leukocytes, especially granulocytes. Patients with a declining number of granulocytes after chemotherapy, can during bacterial sepsis, quickly develop extensive neutropenia and become critically ill. Febrile neutropenia can be a life-threatening condition.. A patient with neutropenia and simultaneous fever or clinical suspicion of systemic infection should be treated as quickly as possible with broad spectrum antibiotics including gram-negative and gram-positive coverage as soon as the required microbiological samples are taken.. The clinical situation is most critical in patients who have not yet started antibiotic treatment. When broad-spectrum antibiotic treatment is started, monitoring the fever may be permitted. Fever is often the only symptom. Some have septicemia without fever. One should therefore also be aware of other symptoms such as lethargia, diarrhea, or visible sign of infection. The local clinical ...
Background: Risk-stratified management of fever with neutropenia (FN), allows intensive management of high-risk cases and early discharge of low-risk cases. No single, internationally validated, prediction model of the risk of adverse outcomes exists for children and young people. An individual patient data (IPD) meta-analysis was undertaken to devise one. Methods: The Predicting Infectious Complications in Children with Cancer (PICNICC) collaboration was formed by parent representatives, international clinical and methodological experts. Univariable and multivariable analyses, using random effects logistic regression, were undertaken to derive and internally validate a risk-prediction model for outcomes of episodes of FN based on clinical and laboratory data at presentation. Results: Data came from 22 different study groups from 15 countries, of 5127 episodes of FN in 3504 patients. There were 1070 episodes in 616 patients from seven studies available for multivariable analysis. Univariable ...
View details of top idiopathic chronic severe neutropenia hospitals in Kolkata. Get guidance from medical experts to select best idiopathic chronic severe neutropenia hospital in Kolkata
Febrile neutropenia is defined as: (1) a single oral temperature above 38.3°C or a temperature of 38.0°C or higher lasting longer than 1 h, and (2) an absolute neutrophil count below 500 cells/^l (Hughes et al. 2002). Of bladder cancer patients undergoing CMV or MVAC chemotherapy regimens, 10 % -14 % meet these established criteria (Gilligan et al. 2003). The importance of febrile neutropenia lies in the fact that infection is the most common cause of fever in the neutropenic setting (50 %) and, in turn, the leading cause of chemotherapy-related death (Schimpff 1986). As such, fever in the context of neutropenia is considered to reflect active infection until proven otherwise.. Was this article helpful?. ...
Abstract. Autoimmune neutropenia (AIN) in children can be divided into 2 forms. In primary AIN, neutropenia is the sole abnormality, and although neutrophil co
Congenital neutropenia (HAX1-related) is an autosomal recessive disorder caused by pathogenic variants in the gene HAX1, which has an increased incidence in Asia and the Middle East. This disorder is characterized by bone marrow failure with reduced neutrophils, presenting in infancy. Patients have multiple bacterial and fungal infections and are at risk for developing acute myeloid leukemia or myelodysplastic syndrome. Some patients develop neurological symptoms, such as psychomotor retardation and/or seizures. Life expectancy may be reduced due to sepsis or malignancy. A genotype-phenotype correlation has been proposed where pathogenic variants that affect only one of the two HAX1 isoforms may result in neutropenia without neurological symptoms.. For information about carrier frequency and residual risk, please see the Expanded Carrier Screen brochure.. ...
Neutropenia occurred after a median period of 4.5 months (ranging 3-6.5 months), following the last RTX infusion in the RA patients and five months (ranging 3-6.5 months) in OAIDs patients. One RA patient had neutrophils ,500/mm3, seven RA patients had neutrophils between 500 and 1,000/mm3, and 17 RA patients had neutrophils between 1,000 and 1,500/mm3. The OAID patients who developed LON were: seven patients with systemic lupus erythematosus, seven patients with vasculitis and one patient with myositis.. Nineteen patients who developed neutropenia after RTX treatment were retreated with RTX. Of those 19, three developed neutropenia again. No patients developed infections or needed growth factor treatment. In the RA patients who developed LON, no baseline risk factors were identified, except age and female gender. LON in RA occurred, but cases were relatively mild. The authors recommend monitoring blood counts following each cycle of RTX.. ...
A new study comparing 2 risk stratification models found that the Clinical Index of Stable Febrile Neutropenia (CISNE) Model is useful for identifying low-risk patients with febrile neutropenia, but the combination of the CISNE Model with the Multinational Association of Supportive Care in Cancer Risk Index Score may help emergency physicians cope with febrile neutropenia more confidently.
Pegfilgrastim was evaluated in three randomized, double blind, controlled studies. Studies 1 and 2 were active-controlled studies that employed doxorubicin 60 mg/m2 and docetaxel 75 mg/m2 administered every 21 days for up to 4 cycles for the treatment of metastatic breast cancer. Study 1 investigated the utility of a fixed dose of Pegfilgrastim. Study 2 employed a weight-adjusted dose. In the absence of growth factor support, similar chemotherapy regimens have been reported to result in a 100% incidence of severe neutropenia (ANC , 0.5 x 109/L) with a mean duration of 5 to 7 days and a 30% to 40% incidence of febrile neutropenia. Based on the correlation between the duration of severe neutropenia and the incidence of febrile neutropenia found in studies with filgrastim, duration of severe neutropenia was chosen as the primary endpoint in both studies, and the efficacy of Pegfilgrastim was demonstrated by establishing comparability to filgrastim-treated patients in the mean days of severe ...
TORONTO, ON and BRISBANE, AUSTRALIA--(Marketwired - December 05, 2016) - Patients at risk of life-threatening infections following chemotherapy could benefit from a new cell-based treatment developed from University of Queensland research.In the weeks following chemotherapy, a patients immune system is depleted as a result of neutropenia -- a decrease in...
The absolute risk reduction by prophylaxis in chemotherapy-induced febrile neutropenia (FN) is largest in patients at highest underlying risk. Therefore, reliable predictive models are needed. Here, we develop and validate such a model for risk of FN during chemotherapy cycles 2-6. A prediction score for risk of FN during the first cycle has recently been published1 . Patients with solid cancers initiating first-line chemotherapy in 2010-2016 were included. Cycle-specific risk factors were assessed by Poisson regression using generalised estimating equations and random split-sampling. The derivation cohort included 4,590 patients treated with 15,419 cycles, wherein 326 (2.1%) FN events occurred. Predictors of FN in multivariable analyses were: higher predicted risk of FN in the first cycle, platinum- or taxane-containing therapies, concurrent radiotherapy, treatment in cycle 2 compared to later cycles, previous FN or neutropenia, and not receiving granulocyte colony-stimulating factors. Each ...
Key clinical point: Risk factors for chemotherapy-induced febrile neutropenia include corticosteroid use and intravenous antibiotics.Major finding: Corticosteroid use was associated with an increased risk of febrile neutropenia, compared with no corticosteroid use (hazard ratio, 1.53; P less than .01).Study details: This retrospective study included 15,971 patients with non-Hodgkin lymphoma or five solid tumors.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...
Infection is a complication in patients receiving treatment for cancer. The promptness of treatment of cancer patients with an infection is imperative as greater than 50% of patients with severe neutropenia will die if untreated during the first 48 hours of infection. The purpose of this study was to analyze the relationship between infection and timeliness of antibiotic administration in neutropenic cancer patients with stratification based on admission status, caregiver characteristics and ordered blood cultures. A chart review study of hospitalized oncology patients diagnosed with neutropenia was used. Information obtained included: admission status, laboratory values, antibiotic information, clinical presentation, medical co-morbidities, and nurse characteristics. In addition, a survey was sent to all nurses involved in the care of patients requesting information regarding educational status, oncology certification, and years of experience.
BACKGROUND Neutropenia recovery (NR) has been associated with worsening preexisting lung injury in up to 50% of critically ill cancer patients. However, only limited relevant data exist in the general population of hematological patients. OBJECTIVES To assess the incidence of acute respiratory deterioration during NR in patients with hematological malignancies. METHODS Adult patients with neutropenia expected to last more than 7 days were included. Worsening of respiratory status (WRS) was defined as a decrease in oxygen saturation of ≥5%, the need for oxygen therapy for ≥24 h, an increase in oxygen flow of ≥50% in patients previously treated with oxygen, or the need for mechanical ventilation. NR was defined as the 3 days preceding or following a neutrophil count of |0.5 × 109/l. RESULTS A total of 16 of 50 patients included in this pilot study experienced WRS during NR (32%), and 13 patients had WRS during neutropenia (26%). The incidence density of WRS was 0.53 (±0.79) episodes per 10
Neutropenia Pipeline Review, H1 2012, provides an overview of the Neutropenia therapeutic pipeline. This report provides information on the therapeutic development for Neutropenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neutropenia. Neutropenia - Pipeline Review, H1 2012 is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team ...
Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said Rolontis eflapegrastim met the primary endpoint of non-inferiority to Neulasta pegfilgrastim in the Phase III RECOVER trial in Read the full 235 word article